Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

What We're Reading

A Sampling of Highlights from the Literature

Article Recommendations from our Deputy and Senior Editors

DOI:  Published August 2018
  • Article
  • Info & Metrics
  • PDF
Loading

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments


Embedded Image

NKs calling in the DCs (by Penn1234567, based on L. Kohidai image, via Wikimedia Commons)

Stimulatory DCs are pivotal in shaping immune responses to tumors. These cells are recruited to the melanoma tumor microenvironment by NK cell–secreted Flt3L, which promotes production of stimulatory DCs. NK cells form synapse-like engagements with DCs that, in turn, increase DC survival. The frequency of these cell types correlates with anti–PD-1 responsiveness.

Barry KC, …, Krummel MF. Nat Med 2018 Jun 25. DOI: 10.1038/s41591-018-0085-8.

Two mechanisms by which tumors encourage immunosuppressive microenvironments


Embedded Image

Controlling the tumor microenvironment (by skeeze via Pixabay)

By comparing tumor cell clones derived from different cells of a pancreatic ductal adenocarcinoma, Li and colleagues find that only some tumors formed from such clones acquire infiltrating T cells, whereas others that produce CXCL1 suppress infiltration. Mixing tumor cell clones that support infiltration with those that do not showed the dominance of suppressive clones. Alonso and colleagues examine recognition of tumor neoantigens in a genetically driven mouse tumor model of lung adenocarcinoma and find that naïve CD4+ T cells are primed in the draining lymph nodes but, rather than become effector cells, either become anergic or are induced to become peripheral Tregs. Thus, tumors appear to promote conditions that recapitulate the mechanisms responsible for peripheral self-tolerance.

Li J, …, Stanger BZ. Immunity 2018 Jun 26. DOI: 10.1016/j.immuni.2018.06.006.

Alonso R, …, Lantz O. Nat Commun 2018 May 29. DOI: 10.1038/s41467-018-04524-x.

Interfaces of malignant and immunologic clonal dynamics in ovarian cancer


Embedded Image

Selection and survival (by Elembis via Wikimedia Commons)

Tumor cell diversity can result from cancer immunoediting. Multiple peritoneal sites from 38 patients with high-grade serous ovarian cancer were assessed for immunologic features that affect tumor cell diversity. Tumor-infiltrating immune cells select for tumor cell clones that then escape immune detection, which can result in spread of tumors lacking infiltrates and resistant to immunotherapy.

Zhang AW, …, Shah SP. Cell 2018 Jun 14;173:1755–1769.e22.

Nonconventional inhibitory CD4+Foxp3−PD-1hi T cells as a biomarker of immune checkpoint blockade activity


Embedded Image

PD-1 blockade could help drain inhibitory subset accumulation (by Semevent via Pixabay)

CD4+Foxp3− cells with high expression of PD-1 accumulate in the tumors of patients with melanoma and non–small cell lung cancer, where they inhibit antitumor responses in a PD-1/PD-L1–dependent manner. This inhibitory CD4+ population has follicular helper T cell–like characteristics. CTLA-4 blockade enhances accumulation of these cells, which interferes with antitumor responses, and the accumulation can potentially be abrogated by concurrent PD-1 blockade.

Zappasodi R, …, Wolchok JD. Cancer Cell 2018 Jun 11;33:1017–1032.e7.

The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy


Embedded Image

Surgery-induced tumor outgrowth linked to wound-healing response (by L. Moreno, David Grant USAF Medical Center)

Early recurrence of breast cancer after surgical resection is not uncommon, raising questions if surgical tumor disruption induces spread or promotes outgrowth of dormant tumors. Using a novel orthotopic mouse model, outgrowth is now linked directly to the surgery-induced, wound-healing inflammatory response. Dormancy is maintained by T cells, and the increase in tumor outgrowth accompanying surgery could be combated with anti-inflammatories. Thus, surgery has systemic effects that can interfere with antitumor responses and promote tumor outgrowth.

Krall JA, …, Weinberg RA. Sci Transl Med 2018 Apr 11;10: eaan3464.

CD8+ T cell subsets that have prognostic value for solid tumors


Embedded Image

Identifying new antitumor cells (by ho7dog via Pixnio)

CD8+ T cells are crucial for antitumor activity. Thommen and colleagues found that a subset of CD8+ T cells expressing high amounts of PD-1 are functionally and transcriptionally distinctive. These cells, which accumulate in non–small cell lung cancer, predict survival and strong antitumor responses in patients treated with anti–PD-1. Using single-cell RNAseq, Savas and colleagues identified a population of tissue-resident memory-like CD103+CD8+ T cells that highly express checkpoint proteins amidst breast cancer–infiltrating T cells. These cells correlated significantly with a better prognosis for patients with triple-negative breast cancer, making the cells targets for modulation.

Thommen DS, …, Zippelius A. Nat Med 2018 Jun 11. DOI: 10.1038/s41591-018-0057-z.

Savas P, …, Loi S. Nat Med 2018 Jun 25. DOI: 10.1038/s41591-018-0078-7.

  • ©2018 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Immunology Research: 6 (8)
August 2018
Volume 6, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Sampling of Highlights from the Literature
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Sampling of Highlights from the Literature
Cancer Immunol Res August 1 2018 (6) (8) 881;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Sampling of Highlights from the Literature
Cancer Immunol Res August 1 2018 (6) (8) 881;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
    • Two mechanisms by which tumors encourage immunosuppressive microenvironments
    • Interfaces of malignant and immunologic clonal dynamics in ovarian cancer
    • Nonconventional inhibitory CD4+Foxp3−PD-1hi T cells as a biomarker of immune checkpoint blockade activity
    • The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy
    • CD8+ T cell subsets that have prognostic value for solid tumors
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Sampling of Highlights from the Literature
  • A Sampling of Highlights from the Literature
  • A Sampling of Highlights from the Literature
Show more What We're Reading
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement